No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
OLMA240517C15000
- 0.15
- 0.000.00%
15min DelayTrading May 14 15:40 ET
0.00High0.00Low
0.00Open0.15Pre Close0 Volume52 Open Interest15.00Strike Price0.00Turnover317.64%IV43.96%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier2DDays to Expiry0.15Time Value100Contract SizeAmericanOptions Type0.1199Delta0.0703Gamma28.48Leverage Ratio-0.0969Theta0.0001Rho3.41Eff Leverage0.0018Vega
Intraday
- 5D
- 1D
No Data
News
OPEN, BCRX and AWIN Among Pre-market Gainers
Olema Pharmaceuticals Announces Promising Breast Cancer Trial Results
Express News | Olema Oncology Announces Interim Results From Phase 1b/2 Palazestrant Study, Says 85% Clinical Benefit Rate Observed To Date Across All CBR-Eligible Patients
Express News | Olema Reports 85% Cbr in Breast Cancer Drug Study
Express News | Olema Pharmaceuticals: Across 50 Treated Patients, Palazestrant (Op-1250) Plus Ribociclib Was Well Tolerated With No New Safety Signals
Express News | Olema Oncology Announces Promising New Data for Palazestrant in Combination With Ribociclib Presented at the 2024 Esmo Breast Cancer Congress
Comments
Although the sale doesn't necessarily signify a negative view on the company's future, absence of insider buying could induce concerns. Other company risks should be considered when investing.
President Sean Bohen Sold A Bunch Of Shares In Olema PharmaceuticalsMr. Garland's expertise in biopharma is predicted to boost late-stage development of Olema's lead product. This could solidify the company's influence in shaping next-gen therapies for women's cancers.
$Olema Pharmaceuticals(OLMA.US$ Olema Pharmaceuticals Announced New Preclinical Data Regarding The Discovery Of Novel Compounds Targeting KAT6, An Epigenetic Target That Is Dysregulated In Breast And Other Cancers
2
Read more